Skip to main content

Table 1 Results of the use of PTNS in OAB Patients

From: Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review

Authors Years Control group PTNS Other   RCT Methods Level Results Female n(%) Mean age   Multicenter
    n Postive % n Postive % R      PTNS Control group PTNS group Control group  
Klingler HC 2000 [13] N/A 15 10 67      N Urodynamic and clinical 3 <10 voids/day <2voids/night PadTest (g) 10 73   N/A   N
Govier FE 2001 [14] N/A 47   71      N Urodynamic 2-3 25% reduction in mean daytime voiding frequency 90   57.4 (24–80)   Y
van Balken MR 2001 [15] N/A 37 22 59      N Clinical 2-3 Request for continued chronice treatment 73   52.5 (23–74)   Y
Vandonink V 2003 [16] N/A 35 24 69      N Clinical 2-3 Continuing treatment 71   57 (29–82)   Y
Vandonink V 2003 [17] N/A 60 34 57      N Urodynamic 2-3 50% reduction      Y
Peters KM 2009 [20] Tolterodine 44 35 80 42 23 55 0.01 Y Clinical 2-3 Improvemtn for cure in 79.5% compared to 54.8% in the tolterodine arm 96 92 57.5 58.2 Y
Peters KM 2010 [22] Sham 110 60 55 110 23 21 <0.001 Y Clinical 1 Improvement in overall bladder symptoms 78 80 62.5 60.2 N
Finazzi-Agro E 2010 [23] Placebo 17 12 71 15 0 0 <0.001 Y Clinical 1 50% reduction 100 100 44.9 45.5 N
Amarenco G 2003 [38] N/A 44 22 50      N Clinical 1   66   53.3   N
van Der pal F 2005 [26] N/A 11 11 100      N Clinical   Improvement in overall bladder symptoms 54.5   51 (33–66)   N
Karademir K 2005 [18] Oxybutynin + PTNS 21 13 62 22 18 82 <0.0001 Y Clinical   Improvement in overall bladder symptoms      Y
de Séze M 2011 [45] N/A 70 58 82.8      N Urodynamic and clinical   Improvement in 82.6% and 83.3% of the patients on day 30 and day 90 regarding symptoms and QoL      N
van Balken MR 2006 [44, 47] N/A 132 43 O/68 S 32,6 O/51,5 S      N Clinical   Improvement QoL 61.3   53 (21–82)   N
Nuhoglu B 2005 [19] N/A 35 19 54      N Urodynamic and clinical   Improvement Urgency and QoL 100   47.3 (35–57)